<p>(A) Telaprevir bound to the wild-type protease with the substrate envelope in blue. Intra- and inter-molecular hydrogen bond interactions are marked as red and grey dashed lines. Telaprevir is also shown bound to the drug-resistant variants (B) R155K, (C) D168A and (D) A156T with the transparent coordinates representing the wild-type structure to better highlight the molecular changes of each mutation. In all cases, catalytic residues are depicted in yellow, the P2 subsite in pink, and the drug molecules in orange.</p
In the era of state-of-the-art inhibitor design and high-resolution structural studies, detection of...
<p>A) Stereo view of penem <b>1</b> interactions in SHV-1 active site. Hydrogen bonds are shown as d...
HIV-1 protease is a key target in treating HIV infection and AIDS, with 10 inhibitors used clinicall...
<p>(A) Danoprevir bound to the wild-type protease with the substrate envelope in blue. Intra- and in...
<p>Surface representations of the wild-type protease in complex with (A) telaprevir, (B) danoprevir,...
<p>The canonical nomenclature for drug moiety positioning is indicated using telaprevir. Telaprevir ...
<p>The Van der Waals contact energy indexes for the wild-type protease and mutant variants R155K, D1...
The protease binding pocket from structure is shown as a transparent surface patch. The residues V3...
<p>(<b>A</b>) Displaying active site of the <i>Pv</i>PM-V Sal-1 (wild type) and its interaction with...
<p>Left: Cartoon representation of an unbound (red, pdb ID 3HVP) aligned to a bound receptor structu...
Left column: visualization of the NS3-4A protease structure and surface of the binding pocket of wi...
<p><b>A</b>) Ribbon structure of the TEV protease (green) was overlaid with the mutant (dark cyan). ...
<p>Similar changes in structure are seen in both genotype 1a and genotype 6a. NS3 protease is shown ...
Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chroni...
HIV-1 protease is a key target in treating HIV infection and AIDS, with 10 inhibitors used clinicall...
In the era of state-of-the-art inhibitor design and high-resolution structural studies, detection of...
<p>A) Stereo view of penem <b>1</b> interactions in SHV-1 active site. Hydrogen bonds are shown as d...
HIV-1 protease is a key target in treating HIV infection and AIDS, with 10 inhibitors used clinicall...
<p>(A) Danoprevir bound to the wild-type protease with the substrate envelope in blue. Intra- and in...
<p>Surface representations of the wild-type protease in complex with (A) telaprevir, (B) danoprevir,...
<p>The canonical nomenclature for drug moiety positioning is indicated using telaprevir. Telaprevir ...
<p>The Van der Waals contact energy indexes for the wild-type protease and mutant variants R155K, D1...
The protease binding pocket from structure is shown as a transparent surface patch. The residues V3...
<p>(<b>A</b>) Displaying active site of the <i>Pv</i>PM-V Sal-1 (wild type) and its interaction with...
<p>Left: Cartoon representation of an unbound (red, pdb ID 3HVP) aligned to a bound receptor structu...
Left column: visualization of the NS3-4A protease structure and surface of the binding pocket of wi...
<p><b>A</b>) Ribbon structure of the TEV protease (green) was overlaid with the mutant (dark cyan). ...
<p>Similar changes in structure are seen in both genotype 1a and genotype 6a. NS3 protease is shown ...
Hepatitis C virus (HCV) infects over 170 million people worldwide and is the leading cause of chroni...
HIV-1 protease is a key target in treating HIV infection and AIDS, with 10 inhibitors used clinicall...
In the era of state-of-the-art inhibitor design and high-resolution structural studies, detection of...
<p>A) Stereo view of penem <b>1</b> interactions in SHV-1 active site. Hydrogen bonds are shown as d...
HIV-1 protease is a key target in treating HIV infection and AIDS, with 10 inhibitors used clinicall...